Loading...
News Article

New investment in light-powered biosensor accelerates the availability of high quality – low cost tests

News

Surfix announces an investment of € 8,5 million by a Dutch consortium consisting of companies Qurin Diagnostics and LioniX International, industry accelerator PhotonDelta and the East Netherlands Development Agency Oost NL for further development of Surfix’s plug-and-play diagnostics platform.

Surfix will use the investment to accelerate the development of its fast, reliable and attractive plug-and-play diagnostics platform for all sorts of point-of-care tests. The initial target applications are early cancer diagnosis, Covid-19 detection and tracing of pathogens in water for aquaculture.

Low cost tests available for the masses

The global Covid-19 pandemic underlines the need for fast and reliable point-of-care diagnostics anytime and anywhere. Also in areas where there is no hospital, clinic or trained medical staff available. A sample taken from the patient is tested on the spot, next to the hospital bed, in the doctor’s office or even at home. Within minutes the result is visible and appropriate action can be taken. It is convenient, in some cases lifesaving, and there is no time-consuming and expensive laboratory work or equipment involved. The availability of a quick and reliable test would mean a huge step forward in the fight against the current and future pandemics. The ultimate goal for Surfix is to make a test that is available for the masses and at the cost of only a few euros.

Unique diagnostics platform

The biosensor of Surfix consists of two significant elements: the most crucial part is the chip in which the actual sensing occurs. The other part is the microfluidics part, in which the biological assay takes place in a small sample volume.

In the sensing part light passes through the chip (comparable to a minuscule glass-fiber spiral) instead of electricity. Biomolecules attached to the surface of the chip can catch other biomolecules out of a sample (for instance blood or urine), based on biorecognition. This causes a change in the properties of the light that is traveling through the chip, which can be detected and read by the sensor system. This change is a measure of the presence of the biomolecule in the sample one is looking for.

Before entering the sensing part of the sensor, any sample needs to be processed (comparable to a very small laboratory). This takes place in microfluidic channels which feed the sample into the sensing part.

For the sensing part Surfix has developed unique nano-coatings which enable the binding of biomolecules and enhance the sensitivity of the sensor, while the microfluidic part is covered with a different nano-coating that repels biomolecules and enhances the flow of the sample through the microfluidic channels.

The plug-and-play diagnostics platform can be used to detect viruses, DNA and RNA, proteins like antibodies and antigens, and other biomolecules.

Combination of Dutch technology

The plug-and-play diagnostics platform combines LioniX’s integrated photonics chip with Surfix’s nanocoatings for the proper functioning of both the sensing part and the microfluidics part. Integrated photonics is a revolutionary technology that allows the development of chips that can sense, capture and process huge amounts of data with light instead of electricity. Using light means that new types of devices and systems such as biosensors can be created that are radically cheaper, faster, smaller, more robust and reliable while using less energy. Qurin will be the launching customer for the platform in the field of cancer diagnostics in a screening setting on a regular basis for the entire adult population. This way Surfix hopes to contribute to the early detection and cure of the cancer patient. Qurin’s novel biomarker technology aims to detect most if not all cancer types in urine, including lung cancer and cancer of the large bowel.

Quintessent appoints Bob Nunn chief operating officer
PI to demonstrate new PIC alignment system at Photonics West
Drut launches 2500 product series with CPO for AI datacentres
III-V Epi advocates GaAs for new lasers
Marvell announces new CPO architecture for custom AI accelerators
Printing high-speed modulators on SOI
Photon IP raises €4.75m for advanced PICs
ANELLO Photonics launches Maritime Inertial Navigation System
Aeluma joins AIM Photonics as full industry member
Imec makes breakthrough with GaAs lasers on silicon
POET acquires Super Photonics Xiamen
Voyant Photonics launches affordable Carbon LiDAR
Penn State makes breakthrough in photonic switching
New nanocrystals could lead to more efficient optical computing
QCi awarded NASA contract to apply Dirac-3 photonic optimisation solver
The Netherlands launches ChipNL Competence Centre
TOPTICA to create chip-integrated lasers for quantum PIC project
NSF selects six pilot projects for National Quantum Virtual Laboratory
SiLC Technologies launches Eyeonic Trace Laser Line Scanner
Southwest Advanced Prototyping Hub awarded $21.3 million CHIPS Act funding
Cambridge Graphene Centre and CORNERSTONE to participate in PIXEurope
Cost-effective lasers for extended SWIR applications
IBM unveils co-packaged optics technology for AI and datacentres
QCi announces $50 million concurrent stock offerings
CHIPS Act funding to be awarded to Coherent, Skywater, and X-Fab
ERC consolidator grant awarded for optoacoustic neural network project
Imec demonstrates InP chiplet integration on 300 mm RF silicon interposer
Ayar Labs raises $155 million for optical I/O
Celestial AI awarded 2024 Start-up to Watch by Global Semiconductor Alliance
Researchers develop “last missing piece” of silicon photonics
Quantum sensors for controlling prosthetics
UPVfab to participate in European Commission photonic chips project

×
Search the news archive

To close this popup you can press escape or click the close icon.
Logo
x
Logo
×
Register - Step 1

You may choose to subscribe to the PIC Magazine, the PIC Newsletter, or both. You may also request additional information if required, before submitting your application.


Please subscribe me to:

 

You chose the industry type of "Other"

Please enter the industry that you work in:
Please enter the industry that you work in: